Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DP-R206 vs Bonviva in Postmenopausal Osteoporosis
NCT01581320Phase 3Completed
- Sponsor
- Alvogen
- Start
- Dec 2011
- Primary completion
- Sep 2012
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ibandronate and vitamin d in postmenopausal osteoporosis (2 arms), sponsored by Alvogen. Primary endpoint: Ratio of subjects whose 25 OHD concentration is less than 15ng/mL at 16 weeks. Started Dec 2011; status: completed.
02
Drugs
ibandronatevitamin d
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01581320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01581320.